Randomized Controlled Preclinical Trial of a Benzodiazepine–Dihydropyridine Hybrid Molecule in Rodent Stroke
Authors:
- Jeney Ramírez‐SánchezJRJeney Ramírez‐Sánchez
- André RexARAndré Rex
- Sarah K. McCannSMSarah K. McCann
- Daniel SchulzeDSDaniel Schulze
- Maylin Wong‐GuerraMWMaylin Wong‐Guerra
- Luis A. Fonseca‐FonsecaLFLuis A. Fonseca‐Fonseca
- Enrique García‐AlfonsoEGEnrique García‐Alfonso
- Ailín Ramírez‐AbreuARAilín Ramírez‐Abreu
- Ricardo LimontaRLRicardo Limonta
- Monika DopatkaMDMonika Dopatka
- Yanier Núñez‐FigueredoYNYanier Núñez‐Figueredo
Open Access
- 5 August 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e040621
Abstract
Background: The 3‐ethoxycarbonyl‐2‐methyl‐4‐(2‐nitrophenyl)‐4,11‐dihydro‐1H‐pyrido[2,3‐b][1,5]benzodiazepine (JM‐20) molecule is a novel multifunctional molecule with potent neuroprotective effects in rat focal cerebral ischemia. To confirm previous results obtained in single laboratories with small sample sizes, and to provide a robust preclinical evidence base for potential clinical development in stroke, we performed a 2‐center preclinical trial with sufficiently large group sizes to detect relevant effects, minimizing biases in experimental design as much as possible (randomization, blinding, predefined in‐ and exclusion criteria) and increasing external and construct validities. Methods: Experimental focal cerebral ischemia was induced by different surgeons in 2 different laboratories on 2 continents, including 2 species (480 mice and 55 rats), different suppliers, mature adult and middle‐aged male animals (age range, 2–16 months) as well as comorbid animals (streptozotocin‐induced diabetes). Results: Although JM‐20 improved functional outcomes after middle cerebral artery occlusion in young adult mice at day 7 and appeared to reduce mortality (not statistically significant), it had no effect on mature adult or comorbid mice. Effect sizes, where statistically significant, were modest, and much lower than those reported in the previous studies. Meta‐analysis of all individual mouse data did not reveal statistically significant different functional outcomes or mortalities between vehicle‐ and JM‐20‐treated animals, although neuroscores and survival were slightly better in JM‐20‐treated animals. In the less‐severe model of permanent cortical focal cerebral ischemia in rats, JM‐20 significantly reduced brain infarction. Conclusions: We were able to confirm the neuroprotective potential of JM‐20. However, effect sizes were substantially lower than previously described in small monocentric trials. Further study is needed to determine whether JM‐20 could be effective in less‐severe cases of focal cerebral ischemia or when used in combination with thrombolysis. Registration: URL: Unique identifier: DOI: 10.17590/asr.0000181 .Keywords
This publication has 22 references indexed in Scilit:
- Multi-targeting effects of a new synthetic molecule (JM-20) in experimental models of cerebral ischemiaPharmacological Reports, 2018
- JM-20 Treatment After MCAO Reduced Astrocyte Reactivity and Neuronal Death on Peri-infarct Regions of the Rat BrainMolecular Neurobiology, 2018
- Behavioral Testing in Rodent Models of Stroke, Part I2016
- Neuroprotection by JM-20 against oxygen-glucose deprivation in rat hippocampal slices: Involvement of the Akt/GSK-3β pathwayNeurochemistry International, 2015
- The effects of JM-20 on the glutamatergic system in synaptic vesicles, synaptosomes and neural cells cultured from rat brainNeurochemistry International, 2015
- Antioxidant effects of JM-20 on rat brain mitochondria and synaptosomes: Mitoprotection against Ca2+-induced mitochondrial impairmentBrain Research Bulletin, 2014
- A novel multi-target ligand (JM-20) protects mitochondrial integrity, inhibits brain excitatory amino acid release and reduces cerebral ischemia injury in vitro and in vivoNeuropharmacology, 2014
- JM-20, a novel benzodiazepine–dihydropyridine hybrid molecule, protects mitochondria and prevents ischemic insult-mediated neural cell death in vitroEuropean Journal of Pharmacology, 2014
- Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in ratsBrain Research, 2010
- Overview of Missing Data Techniques2007